Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02890160
Other study ID # MicroPort_Firesorb_RCT
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 24, 2017
Est. completion date October 2024

Study information

Verified date October 2023
Source Shanghai MicroPort Medical (Group) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The FUTURE-II study is a confirmative clinical trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) after the feasibility and safety of the device has been preliminary confirmed in a small-scale First-in-Man clinical trial.


Description:

This study is a prospective, multicenter, single-blind, randomized controlled trial in patients with coronary artery disease caused by up to two de novo native coronary artery lesions in separate epicardial vessels. The goal is to evaluate the safety and effectiveness of Firesorb to support the approval of the Chinese Food and Drug Administration (CFDA) for this product. The Abbott's XIENCE Everolimus-eluting Coronary Stent System is selected as the control device. 430 subjects will be recruited. All subjects will be 1:1 randomly assigned to experimental group and control group. All subjects will undergo clinical follow-up at 1-month, 6-month, 1-year, 2-year, 3-year, 4-year and 5-year post-index procedure. All subjects will undergo angiographic follow-up at 1-year post-index procedure; of which 3-5 centers will be specified as a subgroup to complete OCT follow-up (n=80, 40 each in test and control group).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 430
Est. completion date October 2024
Est. primary completion date October 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility General Inclusion Criteria: 1. 18-75 years of age, males or non-pregnant females; 2. With silent ischemia evidence, patients with stable or unstable angina, or in patients with old myocardial infarction; 3. Patients with indications for coronary artery bypass graft surgery; 4. To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up. Angiographic Inclusion Criteria: 1. One or two de novo target lesions: 1. If there is one target lesion, a second non-target lesion may be treated but the non-target lesion must be present in a different epicardial vessel, and must be treated first with a successful, uncomplicated result prior to randomization of the target lesion. 2. If two target lesions are present, they must be present in different epicardial vessels and both must satisfy the angiographic eligibility criteria. 3. The definition of epicardial vessels means the LAD, LCX and RCA and their branches. Thus, the patient must not have lesions requiring treatment in e.g. both the LAD and a diagonal branch. 2. Target lesion(s) must be located in a native coronary artery with a visually estimated or quantitatively assessed % diameter stenosis (DS) of = 50% and < 100% with a thrombolysis in myocardial infarction (TIMI) flow of =1 and one of the following: stenosis = 70%, an abnormal functional test (e.g. fractional flow reserve, stress test), unstable angina or post-infarct angina. Lesion(s) must be located in a native coronary artery with RVD by visual estimation of = 2.5 mm and =4.0 mm. Lesion(s) must be located in a native coronary artery with length by visual estimation of = 25 mm. 3. Each target lesion may be covered with one stent. General Exclusion Criteria: 1. Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal; 2. Implantation of stent in target vessel within 1 year , patients with planned intervention again within six months; 3. Severe congestive heart failure (NYHA III and above) ,or left ventricular ejection fraction <40% (ultrasound or left ventricular angiography); 4. Preoperative renal function serum creatinine >2.0mg/DL; receiving hemodialysis; 5. Bleeding, active gastrointestinal ulcers, brain hemorrhage or subarachnoid hemorrhage and half year history of ischemic stroke, antiplatelet agents and would not allow an anticoagulant therapy contraindications patients undergoing antithrombotic therapy; 6. Aspirin, clopidogrel, heparin, contrast agent, poly lactic acid polymer and rapamycin allergies; 7. The patient's life expectancy is less than 12 months; 8. Top participated in other drug or medical device and does not meet the primary study endpoint in clinical trials time frame; 9. Researchers determine patient compliance is poor, unable to complete the study in accordance with the requirements; 10. Heart transplantation patients; 11. The unstable arrhythmia, such as high risk ventricular extrasystole and ventricular tachycardia; 12. Cancer need chemotherapy; 13. Immunosuppression and autoimmune diseases, planned or undergoing immunosuppressive therapy; 14. Planning or being receiving long-term anticoagulant therapy, such as heparin, warfarin, etc; 15. Within six months for elective surgery requires stopping aspirin, Clopidogrel patients; 16. Blood test prompted platelet counts of less than 100x10E9/L or greater than 700x10E9/L, white blood cells than 3x10E9/L; known or suspected liver disease (such as hepatitis); 17. Peripheral vascular disease, 6F catheter is not available. Angiographic Exclusion Criteria: 1. left main coronary artery disease; 2. severe triple vessel lesion and required revascularization. The following exclusion criteria apply to the target lesion(s) or target vessel(s): 1. Aorto-ostial right coronary artery (RCA) lesion (within 3 mm of the ostium). 2. Lesion located within 3 mm of the origin of the Left Anterior Descending Artery (LAD) or left circumflex artery (LCX). 3. Lesion involving a bifurcation with a: 1. side branch = 2.5 mm in diameter, or 2. side branch with diameter stenosis = 50%, or 3. side branch requiring guide wire, or 4. side branch requiring dilatation. 4. Anatomy proximal to or within the lesion that may impair delivery of Firesorb or XIENCE stent: 1. Extreme angulation (= 90°) proximal to or within the target lesion. 2. Excessive tortuosity (= two 45° angles) proximal to or within the target lesion. 3. Moderate or heavy calcification proximal to or within the target lesion. 5. Lesion or vessel involves a myocardial bridge. 6. Vessel contains thrombus as indicated in the angiographic images or by IVUS or OCT. 7. Vessel has been previously treated with a stent at any time prior to the index procedure such that the Firesorb or XIENCE would need to cross the stent to reach the target lesion. 8. Vessel has been previously treated and the target lesion is within 5 mm proximal or distal to a previously treated lesion. 9. Lesion which prevents successful balloon pre-dilatation, defined as full balloon expansion with the following outcomes: 1. Residual %DS is a maximum of < 40% (per visual estimation), = 20% is strongly recommended. 2. TIMI Grade-3 flow (per visual estimation). 3. No angiographic complications (e.g. distal embolization, side branch closure). 4. No dissections National Heart Lung and Blood Institute (NHLBI) grade D-F. 5. No chest pain lasting > 5 minutes. 6. No ST depression or elevation lasting > 5 minutes.

Study Design


Intervention

Device:
Firesorb
Sirolimus Target Eluting Bioresorbable Vascular Scaffold
XIENCE
Everolimus Eluting Coronary Stent System

Locations

Country Name City State
China Fu Wai Hospital Peking Beijing

Sponsors (1)

Lead Sponsor Collaborator
Shanghai MicroPort Medical (Group) Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary In-segment Late Lumen Loss (LLL) (Queue 1) In-segment late lumen loss is defined as the change in minimal lumen diameter (MLD) within the margins of the scaffold/stent and 5mm proximal and 5mm distal to the scaffold/stent from post-procedure to 1 year by angiography. 1 year after index procedure
Secondary The percentage of intima coverage-strut (OCT subgroup) The main secondary endpoint 1 year after index procedure
Secondary Vasomotion (Queue 2) The changes in average lumen diameter before and after intracoronary nitroglycerin 2 year after index procedure
Secondary Acute Success-Device Success Successful delivery and deployment of the assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 30% by visual. From the start of index procedure to end of index procedure
Secondary Acute Success-Procedural Success Achievement of final in-scaffold/stent residual stenosis of less than 30% by visual estimation with successful delivery and deployment of at least one assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for the target lesion without the occurrence of cardiac death, target vessel MI or repeat TLR. At time of procedure up to 7 days in hospital
Secondary Device-oriented composite endpoints (Target Lesion Failure) Target Lesion Failure is defined as the composited endpoints of cardiac death,target vessel myocardial infarction and clinical driven-target lesion revascularization. 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Secondary Patient-oriented clinical composite endpoint (PoCE) Patient-oriented clinical composite endpoint is defined as all cause death, all myocardial infarction, and any revascularization. 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Secondary Death (Cardiac, Vascular, Non-cardiovascular) Cardiac death (CD): Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment. Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Secondary Myocardial Infarction (MI) Attributable to target vessel (TV-MI) Not attributable to target vessel (NTV-MI) 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Secondary Target Vessel Revascularization (TVR) Ischemia-driven TVR (ID-TVR) Not ischemia-driven TVR (NID-TVR) 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Secondary Target Lesion Revascularization (TLR) Ischemia-driven TLR (ID-TLR) Not ischemia-driven TLR (NID-TLR) 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Secondary Any Revascularization 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Secondary Scaffold/Stent Thrombosis (per ARC definition) Timing (acute, sub-acute, late and very late) Evidence (Definite and Probable) 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Secondary Site Diagnosed Angina (SDA) Defined as the study unit by collecting Seattle angina questionnaire (SAQ), doctor angina questionnaire and research units of AE reports incidence of angina pectoris (excludes angina pectoris 0-7 days after index procedure ). 1 month,6 months,1 year,2 years,3 years,4 years and 5 years after index procedure
Secondary Minimum Lumen Diameter (MLD) Including in-scaffold/stent, in-segment lesion, the proximal 5mm of stent, and the distal 5mm of stent. 1 year and 2 years after index procedure
Secondary percentage of diameter stenosis (%DS) Including in-scaffold/stent, in-segment lesion, the proximal 5mm of stent, and the distal 5mm of stent. 1 year and 2 years after index procedure
Secondary Angiographic Binary Restenosis (ABR) Including in-scaffold/stent, in-segment lesion, the proximal 5mm of stent, and the distal 5mm of stent. 1 year and 2 years after index procedure
Secondary Late Lumen Loss (LLL) Including in-scaffold/stent, in-segment lesion, the proximal 5mm of stent, and the distal 5mm of stent. 1 year and 2 years after index procedure
Secondary Acute Stent Recoil Immediately after index procedure
Secondary Descriptive analysis of morphometric, lesion composition and scaffold strut data obtained with OCT OCT endpoint 1 year and 2 years after index procedure
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A